SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas

被引：3
|
作者：
Hamblett, Kevin J. [1 ]
Cochran, Julia [1 ]
Snead, Katie [1 ]
Jin, Steven [1 ]
Yumul, Roma [1 ]
Simmons, Jessica [1 ]
Stone, Ivan [1 ]
Lyski, Ryan [1 ]
Schrum, Jason P. [1 ]
Lim, Andrea R. [1 ]
Clarke, Astrid [1 ]
机构：
[1] Seagen Inc, Bothell, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182400
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A novel CD30-directed antibody-drug conjugate for the treatment of lymphomas
    Hamblett, Kevin J.
    Jin, Steven
    Yumul, Roma
    Chen, Yufei
    Kwon, John
    Simmons, Jessica
    Henderson, Clark
    Sun, Hao
    Schrum, Jason P.
    Lim, Andrea R.
    Bindman, Noah A.
    Canerly, Melissa
    Clarke, Astrid
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies
    Ryan, Maureen
    Lyski, Ryan
    Bou, Lauren
    Heiser, Ryan
    Grogan, Bryan
    Meyer, Dave
    Jin, Steven
    Simmons, Jessica
    Conerly, Melissa
    Senter, Peter
    Jeffrey, Scott
    BLOOD, 2020, 136
  • [3] Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
    Gualberto, Antonio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) : 205 - 216
  • [4] The anti-CD30 antibody-drug conjugate SGN-35 is a potent therapy for the treatment of CD30+malignancies
    Barton, J
    Hamblett, K
    Cerveny, C
    Andreyka, J
    Kissler, K
    Stone, I
    Sun, M
    Senter, P
    Wahl, A
    Francisco, J
    Ihle, N
    ANNALS OF ONCOLOGY, 2005, 16 : 134 - 134
  • [5] SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies
    Ryan, Maureen
    Lyski, Ryan
    Bou, Lauren
    Meyer, David
    Jin, Steven
    Simmons, Jessica
    Benjamin, Dennis
    Senter, Peter
    Jeffrey, Scott
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
    Okeley, Nicole M.
    Miyamoto, Jamie B.
    Zhang, Xinqun
    Sanderson, Russell J.
    Benjamin, Dennis R.
    Sievers, Eric L.
    Senter, Peter D.
    Alley, Stephen C.
    CLINICAL CANCER RESEARCH, 2010, 16 (03) : 888 - 897
  • [7] Brentuximab Vedotin: A CD30-Directed Antibody-Cytotoxic Drug Conjugate
    Newland, Ashley M.
    Li, Jenny X.
    Wasco, Lindsey E.
    Aziz, May T.
    Lowe, Denise K.
    PHARMACOTHERAPY, 2013, 33 (01): : 93 - 104
  • [8] Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas
    Yang, Chen-Yen
    Wang, Linlin
    Pincus, Laura
    McCormick, Frank
    Gill, Ryan
    Ai, Wei
    CANCER RESEARCH, 2017, 77
  • [9] SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies.
    Hamblett, KJ
    Barton, J
    Cerveny, CG
    Andreyka, JB
    Kissler, KM
    Okeley, NM
    Stone, I
    Sutherland, MK
    Sun, MM
    Senter, PD
    Wahl, AF
    Ihle, NC
    BLOOD, 2005, 106 (11) : 181A - 181A
  • [10] THE PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN (SGN-35), AN ANTIBODY-DRUG CONJUGATE (ADC).
    Han, T. H.
    Kennedy, D.
    Hayes, S.
    Lynch, C. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S51 - S51
12345